General Considerations
Statistics can be used in a biological assay as either a method of checking on the validity of conclusions or as a guide to the interpretation of experimental results. The division is sometimes made as one between hypothesis testing and estimation. However, the tool of hypothesis testing can be used as an interpretive aid in conjunction with the tools of estimation, so I prefer to make the divisions in terms of the uses made by the biologist.
If we are to apply statistical procedures to the dominant-lethal trail as a check of validity of conclusions, we would have to consider the inherent theoretical faults in the design. For instance, the animals actually treated constitute a small set of males and any conclusions must be conditional upon that set of males; thus, the probability levels computed are, themselves, random variables, functions of the random choice of males. Or, a typical trial will involve more than one test compound or dose of a test compound against the controls. Thus, any formal probability level computed must take into account questions of multiple comparisons. With comments like these, the statistician can sit in the marble halls of his floating island and throw bolts of doubt at the whole procedure. But, almost any biological assay can be made to suffer from this kind of criticism. At this stage in the develop- anything else appearing in the literature, and 26. but it is still far from ideal. In particular,
If the number of implants can be fitted to it tests the overall mean levels of treat-a binomial (n;p), then the total number of ments and makes no provision for testing implants in M pregnant females will also be effects at specific stages of mutagenesis. In a binomial with parameters (Mn;p). Furfact, a mild mutagen which affects the sperm thermore, if we let the occurrence of dead during only one period will not produce a implants be a set of independent Bernoulli statistically significant treatment effect (al-variables, conditional on the occurrence of though it might produce a significant inter-an implant, with probability of death, r, then action effect); and, thus, the method of Xi, the number of dead implants in the ith testing chosen is ill-suited to the kind of al-female, has a conditional frequency of the ternative hypothesis one From these theoretical considerations, it in April. There is also a significant (p<0.01) can be shown that the total number of dead -upward trend in the number of dead imimplants in M pregnant females has an un-plants. conditional binomial distribution with para--meters (Mn;pvr) or a frequency of the -Methods-of-Analysis Now Being Used
If we assume that the effect of a mutagen will be to change the parameters p (the probability of an implant) or r (the conditional probability of a death, given an implant), then the number of implants and dead implants will continue to have a binomial distribution, even with a treatment effect. Thus, the arcsine transformation will stabilize the variance for both treatment and controls, regardless of the effect of treatment. This is not true of the square-root transformation chosen by Bishop, since that variance stabilization will hold only as long as the probability of a dead implant (r) Figure 1 illustrates these changes. The upper part of the figure displays the average number of implants per pregnant control female (an estimate of n/2 in our binomial model if we assume p is constant at 0.5) across the entire 8 weeks of specific trials. The lower part of the figure displays the arcsine transform of the mean numbers of dead implants. There is an apparent cyclic pattern in the number of implants, with peaks occurring in September and valleys at Pfizer
We nowx have a running computer program which is written in Fortran but is mildly bound to the specific input/output configurations of the PDP-10 computer. Copies of the set of programs are available to anyone who requests them, with the understanding that some minor changes will have to be made in the flow of data. The program produces four pages of output for each treatment group. The first page lists the daily counts of pregnant females, numbers of implants, and rnumbers of dead implants that form the basic input, along with appropriate ratios and 3-day subtotals. This enables the experimenter to see gross and obvious patterns at a glance and to check for transcription errors in the initial input data.
The second page displays mean levels of implants, numbers of pregnant females, implants, dead implants, living implants, and ratios of these for each of the 8 weeks of trial. This enables the investigator to see the entire eight weeks of a single treatment group together, to gain subjective or "gut feeling" insights.
The third page is of the kind displayed in Figure 2 . This is a plot of mean daily levels of a given measure (one of the z statistics described in the previous section or one of the more sophisticated second-order moment Figure 3 (1-p) The mean number of dead implants per pregnant female estimates E(X), and the mean number of implants per pregnant female estimates E(Y). It does not seem possible to find ratios or simple linear combinations of these two estimates that will be an increasing function of both pre-and postimplantation losses. Table 1 displays various indices based upon these two estimates, with the appropriate combinations of parameters of which they are consistent estimators. The columns labeled "conditions" show that for some mutagenic conditions they will tend to remain constant or actually decrease.
It would appear that any attempt to construct a consistent estimator of a combination of parameters that will increase for both pre-and postimplantation losses will have to involve second order moments like the variances or covariance. With clever enough juggling of the formulae for expectation, variance, and covariance, a number of such indices can be found. Two of these indices are displayed in Table 1 . If we use the sample moments of the data, we can construct moment estimators of such indices. These are consistent estimators, but they may be biased, and it might be possible to find more efficient ones by means of maximum likelihood computations.
However, the present state of the art is such that we should first find a useful index that can make sense to the biologist. So, in our first tentative attempts to locate such an index, we have restricted attention to these moment estimators. It would appear, from our first few runs, that the estimator, ln (S'2/1) is the best of those tried, best in the sense that it will declare statistical significance for known mutagens and fails to call significance for many of the situations we have identified as false positives using mean number of dead implants (or its arcsine transform).
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